Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined.
Methods
In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000–2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14–180) was categorised as <4.0, 4.0–<4.5, 4.5–<5.0 and ≥5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary.
Findings
Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5–<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52–0.83, versus <4.0 mmol/L), lower than the 4.0–<4.5 mmol/L band, and not different from ≥5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36–0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96–1.56). The change in potassium correlated weakly with the change in renin (ρ=0.15).
Interpretation
In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5–<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.
Funding
Grants from Taipei Veterans General Hospital (V114C-038) and the National Science and Technology Council, Taiwan (NSTC 113-2314-B-A49-040-MY3, 113-2314-B-A49-009, 113-2321-B-075A-002).